Llovet, Josep M

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 11.

Journal Article

Haber, Philipp K; Castet, Florian; Torres-Martin, Miguel; Andreu-Oller, Carmen; Puigvehí, Marc; Maeda, Miho; Radu, Pompilia; Dufour, Jean-Francois; Verslype, Chris; Czauderna, Carolin; Marquardt, Jens U; Galle, Peter R; Vogel, Arndt; Bathon, Melanie; Meyer, Tim; Labgaa, Ismail; Digklia, Antonia; Roberts, Lewis R; Mohamed Ali, Mohamed A; Mínguez, Beatriz; ... (2023). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology, 164(1), 72-88.e18. Elsevier 10.1053/j.gastro.2022.09.005

Gallon, John; Coto-Llerena, Mairene; Ercan, Caner; Bianco, Gaia; Paradiso, Viola; Nuciforo, Sandro; Taha-Melitz, Stephanie; Meier, Marie-Anne; Boldanova, Tujana; Pérez-Del-Pulgar, Sofía; Rodríguez-Tajes, Sergio; von Flüe, Markus; Soysal, Savas D; Kollmar, Otto; Llovet, Josep M; Villanueva, Augusto; Terracciano, Luigi M; Heim, Markus H; Ng, Charlotte K. Y. and Piscuoglio, Salvatore (2022). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, 16(3), pp. 665-682. Wiley 10.1002/1878-0261.13154

Pinyol, Roser; Torrecilla, Sara; Wang, Huan; Montironi, Carla; Piqué-Gili, Marta; Torres-Martin, Miguel; Wei-Qiang, Leow; Willoughby, Catherine E; Ramadori, Pierluigi; Andreu-Oller, Carmen; Taik, Patricia; Lee, Youngmin A; Moeini, Agrin; Peix, Judit; Faure-Dupuy, Suzanne; Riedl, Tobias; Schuehle, Svenja; Oliveira, Claudia P; Alves, Venancio A; Boffetta, Paolo; ... (2021). Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878]. Journal of hepatology, 75(6), p. 1515. Elsevier 10.1016/j.jhep.2021.09.014

Galle, Peter R; Kudo, Masatoshi; Llovet, Josep M; Finn, Richard S; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Lonardi, Sara; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Liang, Kun; Ogburn, Kenyon D; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C and Zhu, Andrew X (2021). Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver international, 41(11), pp. 2759-2767. Wiley 10.1111/liv.14994

Pinyol, Roser; Torrecilla, Sara; Wang, Huan; Montironi, Carla; Piqué-Gili, Marta; Torres-Martin, Miguel; Wei-Qiang, Leow; Willoughby, Catherine E; Ramadori, Pierluigi; Andreu-Oller, Carmen; Taik, Patricia; Lee, Youngmin A; Moeini, Agrin; Peix, Judit; Faure-Dupuy, Suzanne; Riedl, Tobias; Schuehle, Svenja; Oliveira, Claudia P; Alves, Venancio A; Boffetta, Paolo; ... (2021). Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of hepatology, 75(4), pp. 865-878. Elsevier 10.1016/j.jhep.2021.04.049

Pfister, Dominik; Núñez, Nicolás Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Müller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; ... (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 592(7854), pp. 450-456. Springer Nature 10.1038/s41586-021-03362-0

Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555

Lim, Ho Yeong; Merle, Philippe; Weiss, Karl Heinz; Yau, Thomas; Ross, Paul; Mazzaferro, Vincenzo; Blanc, Jean-Frédéric; Ma, Yuk Ting; Yen, Chia Jui; Kocsis, Judit; Choo, Su Pin; Sukeepaisarnjaroen, Wattana; Gérolami, René; Dufour, Jean-François; Gane, Edward J; Ryoo, Baek-Yeol; Peck-Radosavljevic, Markus; Dao, Thong; Yeo, Winnie; Lamlertthon, Wisut; ... (2018). Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. Clinical cancer research, 24(19), pp. 4650-4661. American Association for Cancer Research 10.1158/1078-0432.CCR-17-3588

Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015]. Nature reviews - clinical oncology, 12(8), p. 436. Nature Publishing Group 10.1038/nrclinonc.2015.121

Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature reviews - clinical oncology, 12(7), pp. 408-424. Nature Publishing Group 10.1038/nrclinonc.2015.103

Llovet, Josep M; Peña, Carol E A; Lathia, Chetan D; Shan, Michael; Meinhardt, Gerold; Bruix, Jordi (2012). Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clinical cancer research, 18(8), pp. 2290-300. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-2175

This list was generated on Thu Mar 28 09:57:22 2024 CET.
Provide Feedback